Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2025 08:10 ET | Source: Cytokinetics, Incorporated

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced its...
November 09, 2025 13:30 ET | Source: Heartflow, Inc.

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the...
November 03, 2025 08:00 ET | Source: Heartflow, Inc.

Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow Plaque Analysis at AHA 2025

MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present...
August 15, 2025 10:28 ET | Source: Recor Medical

Recor Medical Responds to the American Heart Association (AHA) and American College of Cardiology’s (ACC) Updated Guidelines on Renal Denervation for the Treatment of Hypertension

Palo Alto, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), appreciate the American Heart...
November 21, 2022 16:46 ET | Source: Clearday, Inc.

Clearday’s 2022 Year to Date Update

San Antonio, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Clearday, Inc. (OTCQX:CLRD) (the Company or Clearday) is pleased to report its continued development of care for older Americans as it has moved...
November 07, 2022 07:00 ET | Source: InCarda Therapeutics, Inc.

Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions

Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
October 03, 2022 08:00 ET | Source: HeartFlow Holding, Inc.

HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions

MOUNTAIN VIEW, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, announced that the results of the Prospective Randomized Trial of the...
November 12, 2021 07:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021

- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of...
November 08, 2021 07:00 ET | Source: Imara, Inc.

Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D.,...
November 01, 2021 16:01 ET | Source: Esperion Therapeutics, Inc.

Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021

ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021...